AFFILIATIONS
1 Virginia Commonwealth University, Richmond, United States
ABSTRACT
Background: Preclinical studies showed synergy between glucagon-like peptide-1 receptor (GLP-1R) agonists and urolithin A, which activate autophagy and mitophagy. This leads to increased CD8+ T memory cells and enhances chimeric antigen receptor T-cell (CAR T-cell) persistence and antitumor activity in vitro and in xenograft models (Cell Rep Med 2025; 6:102021). Prior studies showed GLP-1R agonist use during CAR T-cell therapy does not increase cytokine release syndrome. This study examines the impact of GLP-1R agonist use in patients with diffuse large B-cell lymphoma (DLBCL) undergoing CAR T-cell therapy on overall mortality.
Methods: This is a retrospective cohort study using the TriNetx Research Network to analyze adults aged 18 or older with DLBCL receiving CAR T-cell therapy from 2015 to 2025. Cohort 1 (n =145) received GLP-1R agonists within 6 weeks of CAR T-cell therapy and continued afterward. Cohort 2 (n =4754) did not receive any GLP-1R agonists before or after CAR T-cell therapy. Propensity score matching (1:1) balanced age, gender, race, and relevant comorbidities such as diabetes, obesity, and ischemic heart disease between the two cohorts. The analysis used the TriNetX platform with its built-in survival and risk assessment tools.
Results: Propensity score matching balanced baseline characteristics of cohort 1 (n =145) and cohort 2 (n =145) for age (median 64 years [IQR, 14] vs 63 years [IQR, 15]; p = 0.7), male gender (69% vs 68%; p = 0.9), white race (72% vs 77%; p = 0.3), black race (12% vs 9%; p =0.3); Asian (7% vs 7%; p = 1), Hispanic/Latino (10% vs 7%; p = 0.4), diabetes (79% vs 78%; p = 0.9), obesity (50% vs 52%; p = 0.7), ischemic heart disease (38.6% vs 39.3%; p = 0.9); prior autologous hematopoietic cell transplantation (auto-HCT) (25% vs 26%; p = 0.8); 4 prior lines of chemotherapy (21% vs 18%; p = 0.6), and lactate dehydrogenase levels (median 216 units/ liter [IQR, 97] in 93% of cohort 1 and 235 units/ liter [IQR, 139] in 94% of cohort 2, p = 0.68). Median follow-up was 365 days [IQR 175] for cohort 1 and 365 days [IQR 195] for cohort 2.
The 1-year mortality rate in cohort 1versus cohort 2 was 15.9% vs 28.3%, with an absolute risk reduction of 12.4% (risk difference: -0.124, 95% CI -0.22 to -0.03; p = 0.01). There was a 44% relative risk reduction in mortality in cohort 1 (risk ratio 0.56, 95% CI 0.36–0.89) and lower odds of death (odds ratio 0.48, 95% CI 0.27–0.85). Kaplan-Meier analysis showed a 1-year survival probability of 81.2% in cohort 1 vs 66.8% in cohort 2 (Log-Rank p = 0.01). Median overall survival remains not reached in either cohort.
Cox proportional hazards regression model to determine the independent impact of cohort membership on overall survival showed cohort 1 had a 49% reduction in the risk of mortality versus cohort 2 (HR: 0.51; 95% CI: 0.33 – 0.77; p = 0.002).Independent predictors of worse survival included male gender (HR 1.2, 95% CI 1.1–1.3; p < 0.001), diabetes (HR 1.3, 95% CI 1.1–1.4; p < 0.001), and ischemic heart disease (HR 1.2, 95% CI 1.1–1.4; p = 0.002). Factors not independently predictive of survival included age; race (White, Black, Asian); Hispanic/ Latino ethnicity; number of previous chemotherapy lines; stage 3 or 4 lymphoma; prior autologous HCT; obesity classes 1, 2, or 3; or type of CAR T-cell therapy (lisocabtagene maraleucel, axicabatagene ciloleucel, or tisangenlecleucel).
Next-line therapy after CAR T-cell infusion was needed in 55.9% (n = 81) of cohort 1 versus 82.1% (n = 119) for cohort 2, with a significant absolute risk reduction of 26% (risk difference was -0.26, 95% CI -0.36 to - 0.16; p < 0.001) at 1 year. GLP-1R agonist use had a 32% relative risk reduction in the need for next-line therapy (risk ratio 0.68, 95% CI 0.58–0.80) and lower odds of treatment progression (odds ratio 0.28, 95% CI 0.16–0.47) at 1 year.
Conclusions: There was a significant reduction in mortality with GLP-1R agonist use in DLBCL patients who had CAR T-cell therapy. These real-world clinical results support preclinical data suggesting that GLP-1R agonists enhance CAR T-cell persistence and antitumor activity, warranting prospective studies.
DISCLOSURES
Baldeep Wirk, MD: No relevant conflicts of interest to declare.